Neovasc Inc. Debt/Equity

Debt/Equity of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.


Highlights and Quick Summary

  • Debt/Equity for the quarter ending March 31, 2022 was 0.27 (a 60.14% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Equity increased by 85.18%
  • Annual Debt/Equity for 2021 was 0.17 (a -96.08% decrease from previous year)
  • Annual Debt/Equity for 2020 was 4.38 (a -506.13% decrease from previous year)
  • Annual Debt/Equity for 2019 was -1.08 (a -38.55% decrease from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Neovasc Inc.

Most recent Debt/Equityof NVCN including historical data for past 10 years.

Interactive Chart of Debt/Equity of Neovasc Inc.

Neovasc Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.27
2021 0.17 0.16 0.15 0.14 0.17
2020 4.38 13.41 -1.73 -1.4 4.38
2019 -1.02 -1.85 -4.59 -4.01 -1.08
2018 -1.75 -1.94 -5.82 -0.86 -1.75
2017 -0.55 0.0 0.0 0.0 -0.55
2016 0.0 -2.23 0.0 0.0
2015 0.0 0.0 0.0 0.0 0.0
2014 0.01 0.01 0.01 0.01 0.01
2013 0.04 0.03 0.03 0.04 0.04
2012 0.04 0.09 0.07 0.06 0.04
2011 0.06 0.06

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.